Recent advances in neuraminidase inhibitor development as anti-influenza drugs (Q30419301)

21 June 2017

Recent advances in neuraminidase inhibitor development as anti-influenza drugs (English)

1 reference

21 June 2017

7

0 references

author name string

Enguang Feng

1

1 reference

21 June 2017

Deju Ye

2

1 reference

21 June 2017

Jian Li

3

1 reference

21 June 2017

Dengyou Zhang

4

1 reference

21 June 2017

Jinfang Wang

5

1 reference

21 June 2017

Fei Zhao

6

1 reference

21 June 2017

Mingyue Zheng

8

1 reference

21 June 2017

Hualiang Jiang

9

1 reference

21 June 2017

Hong Liu

10

1 reference

21 June 2017

16 July 2012

1 reference

21 June 2017

1 reference

21 June 2017

7

1 reference

21 June 2017

9

1 reference

21 June 2017

1527-1536

1 reference

Changing perspective on immunization against influenza

21 June 2017

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Antigenic drift in swine influenza H3 haemagglutinins with implications for vaccination policy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Antigenic drift in the influenza A virus (H3N2) nucleoprotein and escape from recognition by cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Rational design of potent sialidase-based inhibitors of influenza virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

'Flu' and structure-based drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Neuraminidase inhibitors for influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Optimization of small molecule drugs binding to highly polar target sites: lessons from the discovery and development of neuraminidase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Recent advances in anti-influenza agents with neuraminidase as target

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

The war against influenza: discovery and development of sialidase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Anti-influenza virus agents: synthesis and mode of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Advances in the structure-based design of the influenza A neuraminidase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Sales of oseltamivir in Norway prior to the emergence of oseltamivir resistant influenza A(H1N1) viruses in 2007-08.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Global transmission of oseltamivir-resistant influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Neuraminidase-inhibitor resistance testing for pandemic influenza A (H1N1) 2009 in Ontario, Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Neuraminidase inhibitor resistance in influenza viruses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Neuraminidase inhibitor resistance in influenza: assessing the danger of its generation and spread

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Antivirals and resistance: influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Structural and Functional Basis of Resistance to Neuraminidase Inhibitors of Influenza B Viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Complexity in influenza virus targeted drug design: interaction with human sialidases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Characterization of the surface proteins of influenza A (H5N1) viruses isolated from humans in 1997-1998.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Evolution of H5N1 avian influenza viruses in Asia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Influenza viruses and the evolution of avian influenza virus H5N1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Molecular and antigenic evolution and geographical spread of H5N1 highly pathogenic avian influenza viruses in western Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Why are oseltamivir and zanamivir effective against the newly emerged influenza A virus (A/H1N1)?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Characterization of temperature sensitive influenza virus mutants defective in neuraminidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Roles of neuraminidase in the initial stage of influenza virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Structure of the catalytic and antigenic sites in influenza virus neuraminidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Structure of the influenza virus glycoprotein antigen neuraminidase at 2.9 A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Remarkable loop flexibility in avian influenza N1 and its implications for antiviral drug design.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Characterizing loop dynamics and ligand recognition in human- and avian-type influenza neuraminidases via generalized born molecular dynamics and end-point free energy calculations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Novel druggable hot spots in avian influenza neuraminidase H5N1 revealed by computational solvent mapping of a reduced and representative receptor ensemble.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Ensemble-based virtual screening reveals potential novel antiviral compounds for avian influenza neuraminidase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

A novel small-molecule inhibitor of the avian influenza H5N1 virus determined through computational screening against the neuraminidase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

The 2009 pandemic H1N1 neuraminidase N1 lacks the 150-cavity in its active site

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

New antivirals and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

H5N1 influenza pandemic: contingency plans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

A practical synthesis of zanamivir phosphonate congeners with potent anti-influenza activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Syntheses of triazole-modified zanamivir analogues via click chemistry and anti-AIV activities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Synthesis of C-4 and C-7 triazole analogs of zanamivir as multivalent sialic acid containing scaffolds

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Synthesis and anti-influenza virus activity of 4-guanidino-7-substituted Neu5Ac2en derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Synthesis and anti-influenza virus activity of 7-O-alkylated derivatives related to zanamivir

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Structural and Functional Analysis of Laninamivir and its Octanoate Prodrug Reveals Group Specific Mechanisms for Influenza NA Inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Synthesis and anti-influenza evaluation of polyvalent sialidase inhibitors bearing 4-guanidino-Neu5Ac2en derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Synthesis and anti-influenza evaluation of polyvalent sialidase inhibitors bearing 4-guanidino-Neu5Ac2en derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Highly potent and long-acting trimeric and tetrameric inhibitors of influenza virus neuraminidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Dimeric zanamivir conjugates with various linking groups are potent, long-lasting inhibitors of influenza neuraminidase including H5N1 avian influenza.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Synergistic effect of zanamivir-porphyrin conjugates on inhibition of neuraminidase and inactivation of influenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Influenza B virus neuraminidase can synthesize its own inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid beta-protein precursor gamma-secretase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Transition state stabilization by a catalytic RNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Structure-activity relationship studies of novel carbocyclic influenza neuraminidase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Synthesis of tamiflu and its phosphonate congeners possessing potent anti-influenza activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Systematic structure-based design and stereoselective synthesis of novel multisubstituted cyclopentane derivatives with potent antiinfluenza activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Anti-influenza virus activity of peramivir in mice with single intramuscular injection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Syntheses and neuraminidase inhibitory activity of multisubstituted cyclopentane amide derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Structure-based characterization and optimization of novel hydrophobic binding interactions in a series of pyrrolidine influenza neuraminidase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Design, synthesis, inhibitory activity, and SAR studies of pyrrolidine derivatives as neuraminidase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Synthesis of potent pyrrolidine influenza neuraminidase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Structures of aromatic inhibitors of influenza virus neuraminidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Potent inhibition of influenza sialidase by a benzoic acid containing a 2-pyrrolidinone substituent

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Hydrophobic benzoic acids as inhibitors of influenza neuraminidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Design, synthesis, inhibitory activity, and SAR studies of hydrophobic p-aminosalicylic acid derivatives as neuraminidase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Laninamivir prodrug CS-8958, a long-acting neuraminidase inhibitor, shows superior anti-influenza virus activity after a single administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Pharmacokinetics and disposition of CS-8958, a long-acting prodrug of the novel neuraminidase inhibitor laninamivir in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Efficacy of the new neuraminidase inhibitor CS-8958 against H5N1 influenza viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long-retention profile in the mouse respiratory tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Novel sialic acid derivatives lock open the 150-loop of an influenza A virus group-1 sialidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

Influenza type A virus neuraminidase does not play a role in viral entry, replication, assembly, or budding

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

inferred from DOI database lookup

7 January 2021

based on heuristic

Renin inhibitors. Dipeptide analogues of angiotensinogen utilizing a dihydroxyethylene transition-state mimic at the scissile bond to impart greater inhibitory potency

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201200155

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1002/CMDC.201200155

1 reference

21 June 2017

1 reference